Prothena Corporation plc
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Gene G. Kinney
- Full Time Employees
- 67
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 77 Sir John Rogerson’s Quay Dublin DU Ireland D02 VK60
- IPO Date
- Dec 20, 2012
- CIK
- 0001559053
- Website
- prothena.com
- Similar Companies
- Business
- Prothena Corporation plc, a clinical-stage biotechnology company focused on the discovery and development of novel investigational therapies targeting protein dysregulation in neurodegenerative and rare peripheral amyloid diseases, advances a pipeline including PRX012, an anti-amyloid beta monoclonal antibody in Phase 1 for early Alzheimer's disease with data expected in 2025; prasinezumab, a humanized monoclonal antibody targeting alpha-synuclein in Phase 2b for Parkinson's disease and other synucleinopathies; coramitug for transthyretin amyloidosis (ATTR-CM); BMS-986446 and PRX019 targeting tau and TDP-43 respectively in collaboration with Bristol Myers Squibb; and PRX123, a preclinical dual amyloid beta-tau vaccine. The company, founded in 2012 through a spin-off from Elan Corporation plc and headquartered in Dublin, Ireland, with research operations in South San Francisco, California, serves patient populations affected by devastating conditions such as Alzheimer's disease, Parkinson's disease, ALS, and ATTR amyloidosis primarily in the United States and globally through partnerships. Recent developments include the discontinuation of the birtamimab program for AL amyloidosis following the Phase 3 AFFIRM-AL trial failure, a shift emphasizing PRX012 as the lead wholly-owned asset with higher-dose subcutaneous formulations advancing toward topline results in August 2025; progression of partnered programs with Roche on prasinezumab potentially entering Phase 3 by year-end 2025, Novo Nordisk's Phase 2 data for coramitug in the second half of 2025, and Bristol Myers Squibb's ongoing tau and TDP-43 efforts; and initiation of a Phase 1 trial for PRX019 in Q3 2025 alongside a poster presentation on its TDP-43 program at Neuroscience 2025.
Company News
Prothena Corporation plc (NASDAQ:PRTA) Stock Has Average Price Target of $24.57
Prothena (NASDAQ:PRTA) Stock: Insider William Scully Acquires 125,000 Shares
CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
Prothena Corporation plc (NASDAQ:PRTA) Receives $24.57 Consensus PT from Analysts
Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
KMDA or PRTA: Which Is the Better Value Stock Right Now?
PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus
Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates
Prothena Reports Second Quarter 2026 Financial Results and Business Highlights
Prothena (NASDAQ:PRTA) Share Price Passes Below 200-Day Moving Average – Time to Sell?
PRTA Stock Rises Nearly 11% in Six Months: What's Driving It?
SRPT or PRTA: Which Is the Better Value Stock Right Now?
Prothena Posts Q1 Earnings as Revenues Surge on Milestone Payment
Prothena Reports First Quarter 2026 Financial Results and Business Highlights
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy
Prothena Announces Leadership Team Updates
Wall Street Analysts Think Prothena (PRTA) Could Surge 120.19%: Read This Before Placing a Bet
Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson's and Alzheimer's Disease at AD/PD™ 2026
Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy